Slide 1: Corporate Deck
CORPORATE DECK October 1, 2026 DAREBIOSCIENCE.COM | NASDAQ: DARE ©2026 DARÉ BIOSCIENCE, ALL RIGHTS RESERVED
Slide 2: Forward-Looking Statements & Disclaimers
Forward-Looking Statements & Disclaimers This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of Daré Bioscience, Inc. (“Daré” or the “Company”). This presentation discusses potential future drug and medical device produ
Slide 3: Dare to Push Women's Health Forward
DARE TO PUSH WOMEN'S HEALTH FORWARD Bioscience that’s 100% for her. 3
Slide 4: Investment Highlights
Investment Highlights Exclusive Focus on Women's Health Purpose-built portfolio addressing large, underserved markets across women’s health. Commercial Launch Development-Driven Growth Strategy Revenue commencing from product sales in 2026 with Advancing diversified pipeline of late- and mid-stage t
Slide 5: Dare for Her at Every Stage of Life
Dare for Her at Every Stage of Life PLAY PLAN SUPPORT RECLAIM FIGHT Confidence and freedom Empowering your choices Care that supports you and Solutions to help you feel Innovations to help you thrive to live life your way. for today and tomorrow. the life you’re building. like yourself again. and ta
Slide 6: Pipeline Focused on Supporting Every Woman at Every Stage
Pipeline Focused on Supporting Every Woman at Every Stage Women's health is not a single condition. It is a lifelong healthcare journey affecting every woman, at every stage of life. Designed to maintain a Designed for her DARE to healthy vaginal microbiome DARE to sexual experience RESTORE Flora Sy
Slide 7: Why Women's Health, Why Now?
Why Women's Health, Why Now? SEXUAL HEALTH* MENOPAUSE* That is Not a Niche. That is a Significant Market Opportunity. ~20 million ~51 million U.S. women experience U.S. women experience symptoms of low or menopausal symptoms that 27% 80% no sexual arousal3 may benefit from treatment4 of all blockbus
Slide 8: Significant Non-Dilutive Funding From Leading Institutions
Significant Non-Dilutive Funding From Leading Institutions Over $75 Million Awarded to Date Validates Approach and Need Gates Foundation ARPA-H NIH / NICHD $2.5 billion through Sprint for Women’s Health 2030 >$100M $60M+ $10M $5M+ Ovaprene, DARE-LARC1, DARE- DARE-HPV (100% funded Phase DARE-PTB1 (pr
Slide 9: Data Driven Development. Not Just Another Online Compounder.
Data Driven Development. Not Just Another Online Compounder. Built on Science, Clinical Evidence, FDA Development and Product Quality 01 02 03 Clinical Development Proprietary Products Commercial Platform • Conducting clinical studies • Novel formulations and • DARE Health Hub • Generates proprietar
Slide 10: A Commercial Company with a Purpose-Built Women's Health Product Ecosystem
A Commercial Company with a Purpose-Built Women's Health Product Ecosystem 10
Slide 11: Flora Sync LF5
DARE TO RESTORE Flora Sync LF5 Non-hormonal probiotic vaginal capsule designed to restore microbiome balance and support lasting comfort First Sales July 2026 Available without a prescription Vaginal capsule formulated with Limosilactobacillus fermentum LF5 Clinically studied and backed by over 30 y
Slide 12: Sildenafil Cream
DARE TO PLAY Sildenafil Cream* Proprietary topical formulation of the active ingredient in an erectile dysfunction drug (Viagra®) Revenue Generation Expected Q4 2026 Prescribers Already Writing and Patients Engaging† No FDA-approved treatments for female sexual arousal disorder Phase 2b study demons
Slide 13: Turning Clinical Relationships Into Commercial Momentum
Turning Clinical Relationships Into Commercial Momentum Years of product development have created trusted relationships with the providers most likely to adopt new women's health solutions Clinical Relationships Commercial Advantage Built Through Development Long-standing engagement with OBGYNs Exis
Slide 14: Integrated Commercial Platform Designed for Scalable Growth
Integrated Commercial Platform Designed for Scalable Growth Driving patient acquisition, engagement and portfolio expansion through a unified women's health ecosystem Provider Relationships • OBGYN and women's health Digital Marketing specialist engagement • Consumer awareness campaigns • Product re
Slide 15: DARE Health Hub: Now Live
DARE Health Hub: Now Live Direct-to-Patient Growth Engine Central Commercial Platform Product education Telehealth access Prescription fulfillment Patient engagement Product cross-selling 15
Slide 16: Expanding Reach Through Women's Health Media and Influencers
Expanding Reach Through Women’s Health Media and Influencers Podcast appearances and influencer interviews are expanding awareness among women and healthcare audiences Activating trusted voices to educate audiences, increase product discovery and drive engagement across Daré’s commercial ecosystem 1
Slide 17: Development Pipeline
Development Pipeline Robust development strategy to continue to fuel commercial product portfolio 17
Slide 18: Ovaprene: Investigational Hormone-Free Monthly Intravaginal Contraceptive
DARE to PLAN Ovaprene: Investigational Hormone-Free Monthly Intravaginal Contraceptive Physical Barrier 2 3D, knitted polymer barrier to physically block the Ongoing Phase 3 Study with Topline Data Expected 20271 passage of sperm Hormone-Free: Unique dual action MOA (spermiostatic & barrier), no hor
Slide 19: DARE-HPV: Investigational Antiviral Vaginal Insert
DARE to FIGHT DARE-HPV^ Investigational Antiviral Vaginal Insert For Persistent High-Risk HPV Infection Phase 2 Study Commenced May 2026 A proprietary fixed-dose formulation of lopinavir and ritonavir1 in a soft gel vaginal insert Majority of women achieved no dysplasia and undetectable HPV after 12
Slide 20: DARE-HRT1: Monthly Hormone Therapy for Menopause
DARE to RECLAIM DARE-HRT1* Monthly Hormone Therapy for Menopause 503B Compounding and Phase 3-Enabling Activities Underway A proprietary intravaginal ring designed to continuously deliver bio-identical estradiol and progesterone over 28 days Statistically significant improvements in hot flashes, nig
Slide 21: DARE-VVA1: Vaginal Insert for Genitourinary Syndrome of Menopause
DARE to RECLAIM DARE-VVA1^ Investigational Vaginal Insert for Genitourinary Syndrome of Menopause (GSM) Phase 2 Study Preparations Underway A proprietary hormone-free vaginal insert containing tamoxifen for sexual pain post-menopause or breast cancer treatment. Statistically significant improvements
Slide 22: DARE-FRT1 / DARE-PTB1 Progesterone Intravaginal Ring
DARE to SUPPORT DARE-FRT1 / DARE-PTB1 Investigational Sustained-Release Progesterone Intravaginal Ring for Pregnancy Maintenance Phase 1 Study Preparation Underway A proprietary intravaginal ring designed to deliver bio-identical progesterone as an alternative to daily injections or vaginal gel Pote
Slide 23: Multiple Pipeline Expansion Opportunities from Earlier Stage Programs
Multiple Pipeline Expansion Opportunities from Earlier Stage Programs* ESTIMATED ADDRESSABLE PHASE 3 / PROGRAM MARKET PRE-CLINICAL PHASE 1 PHASE 2 PIVOTAL Australia R&D Vaginal diclofenac once-daily thermosetting 50% menstruating women Phase 1 study completed 2023 DARE-PDM1^ Cash Rebate hydrogel for
Slide 24: Corporate Overview
Corporate Overview 24
Slide 25: Financial Snapshot
Nasdaq: DARE Financial Snapshot Start of Product Revenue Generation in 2026 with Commercial Launch of Flora Sync LF5 in Q2 2026 and DARE to PLAY Expected in Q4 2026 ~$12.6 M ~$16.0 M ~526 K ~19.7 M Cash 1 Market Cap Trading Volume Shares Outstanding As of June 30, 2026 As of September 29, 2026 3-mon
Slide 26: Management Team
Management Team Sabrina Martucci Johnson David Friend, PhD MarDee Haring-Layton Jessica Hatheway Annie Thurman, MD, FACOG Mark Walters CEO & President Chief Scientific Officer Chief Accounting Officer VP, Clinical Operations Medical Director VP, Operations Robert Charboneau Jennifer Kiang Christine
Slide 27: Multiple Near-Term Catalysts with Potential for Meaningful Value Creation
Multiple Near-Term Catalysts with Potential for Meaningful Value Creation PRODUCT / PROGRAM GRANT-FUNDED INFLECTION EVENT TIMING¹ VALUE CREATION Revenue; real-world data; estimated 20 million DARE to PLAY2 Prescription dispensing; product revenue Q4 2026 underserved women³ with no FDA-approved treat
Slide 28: Why Daré, Why Now.
Why Daré, Why Now. Transitioning to a Commercial-Stage Company with Two Revenue-Generating Products Launching and a Purpose- Built Development Pipeline Advancing to Support Women at Every Stage of Life Commercial Scalable Commercial Engine Inflection Point in Place First product revenue commencing D
Slide 29: Daring to Put Her Health First
Daring to Put Her Health First DAREBIOSCIENCE.COM | NASDAQ: DARE ©2026 DARÉ BIOSCIENCE, ALL RIGHTS RESERVED
Slide 30: Appendix
Appendix DAREBIOSCIENCE.COM | NASDAQ: DARE ©2026 DARÉ BIOSCIENCE, ALL RIGHTS RESERVED 30
Slide 31: FDA Approved Product: XACIATO (Clindamycin Phosphate) Vaginal Gel 2%
FDA APPROVED PRODUCT: XACIATO (Clindamycin Phosphate) Vaginal Gel 2% PRODUCT INFO XACIATO [zah-she-AH-toe] (clindamycin phosphate) vaginal gel 2% is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis (BV) in females 12 years of age and older* • Available nationwide via co
Slide 32: XACIATO Selected Safety Information
XACIATO (Clindamycin Phosphate) Vaginal Gel 2% SELECTED SAFETY INFORMATION • XACIATO is contraindicated in individuals with a history of hypersensitivity to clindamycin or lincomycin. • Clostridioides difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents,
Slide 33: Oral Sildenafil provided a compelling proof of concept for FSAD
Oral Sildenafil provided a compelling proof of concept for FSAD STATISTICALLY SIGNIFICANT INCREASES STATISTICALLY SIGNIFICANT IMPROVEMENT IN VAGINAL PULSE AMPLITUBE (VPA)1 IN GENITAL STIMULATION (FIEI)2 † Question #2 – “After taking study medication, the Pfizer VPA Clinical Lab Study – Oral Viagra P
Slide 34: Path Forward for Sildenafil Cream for Treatment of FSAD
Path Forward for Sildenafil Cream for Treatment of FSAD EXPLORATORY PHASE 2B CLINICAL STUDY1 CLNICAL DEVELOPMENT PLAN • The Phase 2b Clinical Study (ID# NCT04948151) was designed to • Sildenafil Cream has potential to be a first-in-category option with evaluate Sildenafil Cream vs. placebo over 12 w
Slide 35: Sildenafil Cream Phase 2b in FSAD
Sildenafil Cream Phase 2b in FSAD EXPLORATORY POST-HOC ANALYSES* Post-Hoc Analysis Results from Proposed Phase 3 population: FSAD with or without concomitant decreased desire Sildenafil Cream Placebo Cream • Post-hoc analyses were conducted on enrollment female sexual Endpoint 3.6% (N=33) (N=32) P v
Slide 36: Sildenafil Cream Phase 2b in FSAD: Summary of Safety Results
Sildenafil Cream Phase 2b in FSAD SUMMARY OF SAFETY RESULTS Sildenafil Cream was well tolerated by exposed users and their sexual partners. • During the 12-week double-blind dosing period, there were 78 TEAEs reported by 29 of the 99 Sildenafil Cream-assigned participants and 65 TEAEs reported by 28
Slide 37: Sildenafil Cream, 3.6% Pharmacokinetic and Pharmacodynamic Studies
Sildenafil Cream, 3.6% Pharmacokinetic and Pharmacodynamic Studies PHASE 1 & PHASE 2A STUDY RESULTS THERMOGRAPHY STUDY RESULTS* • Demonstrated time to effect (11-15 minutes) Phase 1 Study of SST-6007 (Sildenafil Cream, 3.6%)1 • Positive cognitive arousal responses were noted Normal healthy postmenop
Slide 38: Notable Publications for Daré's Sildenafil Cream, 3.6%
Notable Publications for Daré’s Sildenafil Cream, 3.6% PUBLICATION AUTHOR(S) TITLE Impact of age, race, and medication use on efficacy endpoints in a randomized controlled Sexual Medicine, Volume 12, Issue 5, October 2024 Johnson, et al. trial of topical sildenafil cream for the treatment of female
Slide 39: Ovaprene Pre-Pivotal Study Results
OVAPRENE® Investigational Hormone-Free Monthly Intravaginal Contraceptive OVAPRENE® PRE-PIVOTAL STUDY RESULTS OVAPRENE® PRE-PIVOTAL The Ovaprene® Pre-Pivotal Postcoital Test (PCT) STUDY study met its primary endpoint. • In 100% of women and cycles, Ovaprene prevented the requisite number of sperm fr
Slide 40: Ovaprene Pivotal Study and Regulatory Strategy
OVAPRENE® Investigational Hormone-Free Monthly Intravaginal Contraceptive 1 Pivotal study ongoing • Enrollment is ongoing; recruiting at five study sites supported by grant funding received in November 2024; currently anticipate enrollment will be U.S. Review via a premarket approval (PMA) applicati